论文部分内容阅读
乙酰甲孕酮(MPA)和乙酰甲地孕酮(MA)已经被广泛应用于晚期乳癌治疗失败后的挽救性治疗。在以前甲孕酮Ⅲ期临床试验中已显示,大剂量的甲孕酮有效率高于标准剂量。本临床试验的目的是试图确定大剂量的甲地孕酮治疗晚期乳癌病人是否比标准剂量更为有效。本研究随机选择了172例晚期乳癌病人,分成口服乙酰甲地孕酮标准剂员(160mg/天)和大剂量(800mg/天)两组。两组患者在治疗前的情况相似。
Methaprogesterone (MPA) and methazeprodone (MA) have been widely used for salvage treatment after failure of advanced breast cancer treatment. In the previous phase III trial of medroxyprogesterone, it has been shown that large doses of medroxyprogesterone are more effective than standard doses. The purpose of this clinical trial is to try to determine if high-dose megestrol acetate is more effective than standard doses in patients with advanced breast cancer. In this study, 172 patients with advanced breast cancer were randomly selected and divided into two groups: oral methaproterone standard (160 mg/day) and high-dose (800 mg/day) groups. The two groups were similar before treatment.